Last reviewed · How we verify

Chronic infection caused by Hepatitis D virus — Treatment Landscape & Competitive Intelligence

Chronic infection caused by Hepatitis D virus (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Chronic infection caused by Hepatitis D virus, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Hepcludex BULEVIRTIDE MYR GmbH Sodium/bile acid cotransporter

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. MYR GmbH · 1 drug in Chronic infection caused by Hepatitis D virus

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Chronic infection caused by Hepatitis D virus:

Cite this brief

Drug Landscape (2026). Chronic infection caused by Hepatitis D virus — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/chronic-infection-caused-by-hepatitis-d-virus. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing